I
RARE icon

InceptionR’s Ultragenyx Pharmaceutical RARE Stock Holding History

InceptionR’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,714
Closed -$453K – 852
2025
Q4 		$453K Buy
+19,714
New +$648K 0.13% 305
2025
Q2 		– Sell
-12,803
Closed -$464K – 815
2025
Q1 		$464K Buy
12,803
+4,576
+56% +$190K 0.14% 294
2024
Q4 		$346K Sell
8,227
-6,416
-44% -$318K 0.08% 413
2024
Q3 		$813K Buy
14,643
+6,166
+73% +$314K 0.2% 191
2024
Q2 		$348K Buy
8,477
+4,188
+98% +$179K 0.1% 373
2024
Q1 		$200K Buy
+4,289
New +$202K 0.05% 512

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

InceptionR's RARE Position: Q1 2026 in Review

InceptionR sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 19,714 shares — an estimated $453K sold.

InceptionR first reported a position in RARE in Q1 2024 and held it in 6 quarters. The position peaked at $813K in Q3 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • InceptionR reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • InceptionR sold 19,714 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $453K.
  • InceptionR first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and held it in 6 quarters.
  • InceptionR's Ultragenyx Pharmaceutical position peaked at $813K in Q3 2024.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on InceptionR's 13F filing for Q1 2026, filed 14 May 2026.